Evidence map›Paper›PMID 34294093›Full record

ArticleBioData mining2021

Evaluating risk detection methods to uncover ontogenic-mediated adverse drug effect mechanisms in children.

Nicholas P Giangreco, Nicholas P Tatonetti

Open access · goldAbstract read
In one paragraph

Article in BioData mining, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Nicholas P GiangrecoDepartments of Systems Biology and Biomedical Informatics, Columbia University, 622 W. 168th Street, New York, NY, 10032, USA.ORCID https://orcid.org/0000-0001-8138-4947
Nicholas P TatonettiDepartments of Systems Biology and Biomedical Informatics, Columbia University, 622 W. 168th Street, New York, NY, 10032, USA. npt2105@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-2700-2597
Columbia University · USColumbia University Irving Medical Center · US

Funding

TRAINING IN CELLULAR, MOLECULAR AND BIOPHYSICAL STUDIEST32GM008224 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI LIEM, RONALD K. · 1987 to 2021
$9.9M
Precision Pharmacology and Pharmacovigilance: Leveraging AI to address drug safety knowledge gapsR35GM131905 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Nicholas P Tatonetti · 2019 to 2026
$3.3M
NIGMS NIH HHS R35 GM131905NIGMS NIH HHS R35GM131905NIGMS NIH HHS T32 GM008224
6 · The paper itself

Abstract

backgroundIdentifying adverse drugs effects (ADEs) in children, overall and within pediatric age groups, is essential for preventing disability and death from marketed drugs. At the same time, however, detection is challenging due to dynamic biological processes during growth and maturation, called ontogeny, that alter pharmacokinetics and pharmacodynamics. As a result, methodologies in pediatric drug safety have been limited to event surveillance and have not focused on investigating adverse event mechanisms. There is an opportunity to identify drug event patterns within observational databases for evaluating ontogenic-mediated adverse event mechanisms. The first step of which is to establish statistical models that can identify temporal trends of adverse effects across childhood.

resultsUsing simulation, we evaluated a population stratification method (the proportional reporting ratio or PRR) and a population modeling method (the generalized additive model or GAM) to identify and quantify ADE risk at varying reporting rates and dynamics. We found that GAMs showed improved performance over the PRR in detecting dynamic drug event reporting across child development stages. Moreover, GAMs exhibited normally distributed and robust ADE risk estimation at all development stages by sharing information across child development stages.

conclusionsOur study underscores the opportunity for using population modeling techniques, which leverage drug event reporting across development stages, as biologically-inspired detection methods for evaluating ontogenic mechanisms.

Indexed as

Child developmentDynamicsModelingPediatricsPharmacovigilance

Identifiers

PMID34294093
PMCPMC8296590
OpenAlexW3139341041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.